Novel antiplatelet agents in the prevention of cardiovascular complications – focus on ticagrelor

References

• JenningsLKRole of platelets in atherothrombosisAm J Cardiol2009103410
   PubMed Web of Science ®Google Scholar
• AwtryEALoscalzoJCardiovascular drugs – aspirinCirculation200010112061218
   PubMed Web of Science ®Google Scholar
• PatronoCCollerBFitzGeraldGAHirshJRothGPlatelet-active drugs: the relationships among dose, effectiveness, and side effects. The Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyChest2004126Suppl 3S234S264
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ CollaborationCollaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ20023247186
   PubMed Web of Science ®Google Scholar
• YusufSZhaoFMehtaSREffects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevationN Eng J Med2001345494502
   PubMed Web of Science ®Google Scholar
• SnoepJDHovensMMEikenboomJCvan der BomJGJukemaJWHuismanMVClopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysisAm Heart J2007154221231
   PubMed Web of Science ®Google Scholar
• GoriAMMarcucciRMiglioriniAIncidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stentsJ Am Coll Cardiol200852734739
   PubMed Web of Science ®Google Scholar
• KamathSBlannandADLipGYHPlatelet activation: assessment and quantificationEur Heart J20012215611571
   PubMed Web of Science ®Google Scholar
• ShankarHKunapuliSPIs the P2Y1 receptor a better target for antithrombotic drugs?Drug Discov Today20052285290
   Google Scholar
• QuintonTMMurugappanSKimSJinJKunapuliSPDifferent G protein-coupled signaling pathways are involved in alpha granule release from human plateletsJ Thromb Haemost20042978984
   PubMed Web of Science ®Google Scholar
• HamiltonJProtease-activated receptors as targets for antiplatelet therapyBlood Rev2009236165
   PubMed Web of Science ®Google Scholar
• KakkosSKNicolaidesANS-18886 ServierCurr Opin Investig Drugs2002313241327
   PubMedGoogle Scholar
• MichelsonADP2Y12 antagonism: promises and challengesArterioscler Thromb Vasc Biol2008283338
   PubMed Web of Science ®Google Scholar
• SabatineMSNovel antiplatelet strategies in acute coronary syndromesCleve Clin J Med200976814
   Google Scholar
• ManginPOhlmannPEcklyACazenaveJPLanzaFGachetCThe P2Y1 receptor plays an essential role in the platelet shape change induced by collagen when TxA2 formation is preventedJ Thromb Haemost20042969977
   PubMed Web of Science ®Google Scholar
• StoreyRFBiology and pharmacology of the platelet P2Y12 receptorCurr Pharm Des20061212551259
   PubMed Web of Science ®Google Scholar
• JinJQuintonTZhangJRittenhouseSEKunapuliSPAdenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb) beta(3) and ADP receptorsBlood200299193198
   PubMed Web of Science ®Google Scholar
• SchomigATicagrelor – is there need for a new player in the antiplatelet-therapy field?N Engl J Med20091111081111
   Google Scholar
• KushnerFGHandMSmithSCJr2009focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction and ACC/AHA/SCAI guidelines on percutaneous coronary interventionJ Am Coll Cardiol [serial on the Internet]. 2009 [cited 2009 Nov 18];5422052241 http://content.onlinejacc.org/cgi/content/full/j.jacc.2009.10.015 Accessed 2009 December 16.19942100
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention [cited 2009 Oct]. http://www.nice.org.uk/TA182 Accessed 2009 December 16.
   Google Scholar
• WallentinLVarenhorstCJamesSPrasugrel achieves greater and faster P2Y12 receptor mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery diseaseEur Heart J200829213018055486
   PubMed Web of Science ®Google Scholar
• BrandtJTCloseSLIturriaSJCommon polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrelJ Thromb Haemost200752429243617900275
   PubMed Web of Science ®Google Scholar
• VarenhorstCJamesSErlingeDGenetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery diseaseEur Heart J20093017441752
   PubMed Web of Science ®Google Scholar
• MegaJLCloseSLWiviottSDCytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomesCirculation200911925532560
   PubMed Web of Science ®Google Scholar
• SmallDSFaridNAPayneCDEffects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrelJ Clin Pharmacol200848475484
   PubMed Web of Science ®Google Scholar
• BrandtJTPayneCDWiviottSDA comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formationAm Heart J2007153916
   PubMed Web of Science ®Google Scholar
• NiitsuYJakubowskiJASugidachiAAsaiFPharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activitySemin Thromb Hemost200531184194
   PubMed Web of Science ®Google Scholar
• WiviottSDBraunwaldEAngiolilloDJGreater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel – thrombolysis in myocardial infarction 38Circulation20081181626163618757948
   PubMed Web of Science ®Google Scholar
• WiviottSDBraunwaldEMcCabeCHPrasugrel versus clopidogrel in patients with acute coronary syndromesN Engl J Med20073572001201517982182
   PubMed Web of Science ®Google Scholar
• AntmanEMWiviottSDMurphySAEarly and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel – Thrombolysis In Myocardial Infarction) analysisJ Am Coll Cardiol20085120282033
   PubMed Web of Science ®Google Scholar
• WallentinLBeckerRCBudajATicagrelor versus clopidogrel in patients with acute coronary syndromesN Engl J Med200936110451057
   PubMed Web of Science ®Google Scholar
• TantryUSBlidenKPGurbelPAAZD6140Expert Opin Investig Drugs200716225229
   PubMed Web of Science ®Google Scholar
• PetersGRButlerKAWinterHRMultiple-dose pharmacokinetics (PK) and pharmacodynamics (PD) of the reversible, orally active ADP receptor antagonist AZD6140 [abstract]Eur Heart J200627Suppl 1S758
   PubMedGoogle Scholar
• CAPRIE Steering CommitteeA randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)Lancet199634813291339
   PubMed Web of Science ®Google Scholar
• HarringtonRAStoneGWMcNultySPlatelet inhibition with cangrelor in patients undergoing PCIN Engl J Med200936123182329
   PubMed Web of Science ®Google Scholar
• HustedSEmanuelssonHHeptinstallSSandsetPMWickensMPetersGPharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirinEur Heart J20062710381047
   PubMed Web of Science ®Google Scholar
• CannonCPHustedSHarringtonRASafety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trialJ Am Coll Cardiol2007501844185117980250
   PubMed Web of Science ®Google Scholar
• GurbelPABlidenKPButlerKRandomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET studyCirculation200912025112522
   Web of Science ®Google Scholar
• StoreyRFThorntonSMLawranceRTicagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3Platelets200920341348
   PubMed Web of Science ®Google Scholar
• AstraZeneca press release Results from two phase II Trials add to understanding of Brilinta (ticagrelor) and how it works in the body [cited 2009 Nov 18]. http://www.astrazeneca.com/media/latest-press-releases/2009/Brilinta_Phase_II_AHA?itemId=7499699 Accessed 2009. December 16.
   Google Scholar
• AstraZeneca press release Phase III head to head trial showed ticagrelor reduced cardiovascular death and heart attacks over clopidogrel in acute coronary syndromes patients [cited 2009 Aug 30]. http://www.astrazeneca.com/media/latest-press-releases/2009/plato-esc?itemId=6868332 Accessed 2009 December 16.
   Google Scholar
• AstraZeneca press release BRILINTA demonstrated greater efficacy over clopidogrel in the most urgent clinical setting: patients with ST-segment elevation myocardial infarction and planned percutaneous coronary intervention (PCI) [cited 2009 Nov 16]. http://www.astrazen-eca.com/media/latest-pressreleases/2009/PLATO_STEMI?itemId=7476684 Accessed 2009 December 16.
   Google Scholar
• Clinical Trials.gov [homepage on the Internet]. A study of the antiplatelet effects comparing AZD6140 with clopidogrel responder and non-responders (RESPOND) [updated 2009 Apr 23]. http://clinicaltrials.gov/ct2/show/NCT00642811 Accessed 2009 December 16.
   Google Scholar
• MüllerIBestaFSchulzCMassbergSSchönigAGawazMPrevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placementThromb Haemost20038978378712719773
   PubMed Web of Science ®Google Scholar
• GurbelPABlidenKPAntoninoMAbstract 5901: the effect of ticagrelor in stable coronary artery disease patients nonresponsive to clopidogrel: the RESPOND study [abstract]Circulation2009120SupplS1173
   Google Scholar
• GreenbaumABGrinesCLBittlJAInitial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trialAm Heart J2006151689.e1689.e10
   PubMed Web of Science ®Google Scholar
• StoreyROldroydKWilcoxROpen multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromesThromb Haemost200185401407
   PubMed Web of Science ®Google Scholar
• FugateSECuddLACangrelor for treatment of coronary thrombosisAnn Pharmacother200640925930
   PubMed Web of Science ®Google Scholar
• Clinical Trials.gov [homepage on the Internet]. A clinical trial to demonstrate the efficacy of cangrelor (PCI) [updated 2009 May 18]. http://clinicaltrials.gov/ct2/show/NCT00305162 Accessed 2009 December 16.
   Google Scholar
• Clinical Trials.gov [homepage on the Internet]. Cangrelor versus standard therapy to achieve optimal management of platelet inhibition (PLATFORM) [updated 2009 May 18]. http://clinicaltrials.gov/ct2/show/NCT00385138 Accessed 2009 December 16.
   Google Scholar
• The Medicines Company press release The medicines company discontinues Phase 3 CHAMPION clinical trial program of cangrelor [cited 2009 May 13]. http://ir.themedicinescompany.com/phoenix.zhtml?c=122204&p=irol-newsArticle&ID=1287788&highlight Accessed 2009 December 16.
   Google Scholar
• Clinical Trials.gov [homepage on the Internet]. Maintenance of platelet inhibition with cangrelor (BRIDGE) [updated 2009 Dec 9]. http://clinicaltrials.gov/ct2/show/NCT00767507 Accessed 2009 December 16.
   Google Scholar
• GretlerDDConleyPBAndreP“First in human” experience with PRT060128, a new direct-acting, reversible, P2Y12 inhibitor for IV and oral use [abstract]J Am Coll Cardiol20079Suppl2326
   Google Scholar
• LieuHDConleyPBAndrePInitial intravenous experience with PRT060128 (PRT128), an orally-available, direct-acting, and reversible P2Y12 inhibitor [abstract]J Thromb Haemost20075Suppl 2P-T-292
   Google Scholar
• Clinical Trials.gov [homepage on the Internet]. Safety and efficacy study of adjunctive antiplatelet therapy prior to primary PCI in patients with STEMI (ERASE-MI) [updated 2008 Jul 22]. http://clinicaltrials.gov/ct2/show/NCT00546260 Accessed 2009 December 16.
   Google Scholar
• BergerJSRoeMTGibsonCMSafety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the early rapid reversal of platelet thrombosis with intravenous elinogrel before PCI to optimize reperfusion in acute myocardial infarction (ERASE MI) pilot trialAm Heart J20091586998.e11004.e119958867
   PubMed Web of Science ®Google Scholar
• Clinical Trials.gov [homepage on the Internet]. A Phase 2 safety and efficacy study of PRT060128, a novel intravenous and oral P2Y12 inhibitor, in non-urgent PCI (INNOVATE-PCI) [updated 2009 Mar 29]. http://clinicaltrials.gov/ct2/show/NCT00751231 Accessed 2009 December 16.
   Google Scholar
• WangYVinceletteJda CunhaVA novel P2Y(12) adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog modelsThromb Haemost2007975847855
   PubMed Web of Science ®Google Scholar
• PostJMAlexanderSWangYXNovel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterizationThromb Res200812253354018539312
   PubMed Web of Science ®Google Scholar
• BeckerRCMoliternoDJJenningsLKSafety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II studyLancet200937391992819286091
   PubMed Web of Science ®Google Scholar
• MorrowDASciricaBMFoxKATRA 2°P-TIMI 50 InvestigatorsEvaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the thrombin-receptor antagonist in secondary prevention of atherothrombotic ischemic events (TRA 2 degrees P)-TIMI 50 trialAm Heart J200915833534119699854
   PubMed Web of Science ®Google Scholar
• Clinical Trials.gov [homepage on the Internet]. Trial to assess the effects of SCH 530348 in preventing heart attack and stroke in patients with acute coronary syndrome (TRA-CER) [updated 2009 Nov 23]. http://clinicaltrials.gov/ct2/show/NCT00527943 Accessed 2009 December 16.
   Google Scholar
• Clinical Trials.gov [homepage on the Internet]. Safety and tolerability of E5555 and its effects on markers of intravascular inflammation in subjects with coronary artery disease [updated 2009 Sep 1]. http://clinicaltrials.gov/ct2/show/NCT00312052 Accessed 2009 December 16.
   Google Scholar
• Clinical Trials.gov [homepage on the Internet]. Safety and tolerability of E5555 and its effects on markers of intravascular inflammation in subjects with acute coronary syndrome [updated 2009 Sep 2]. http://clinicaltrials.gov/ct2/show/NCT00548587 Accessed 2009 December 16.
   Google Scholar
• NapoliCAldiniGWallaceJLEfficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosisProc Natl Acad Sci U S A20029916891694
   PubMed Web of Science ®Google Scholar
• BousserMGAmarencoPChamorroAfor PERFORM Study InvestigatorsRationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) studyCerebrovasc Dis200927509518
   PubMed Web of Science ®Google Scholar
• ChamorroATP receptor antagonism: a new concept in atherothrombosis and stroke preventionCerebrovasc Dis200927202719439937
   PubMed Web of Science ®Google Scholar
• CayatteAJDuYOliver-KrasinskiJLavielleGVerbeurenTJCohenRAThe thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosisArterioscler Thromb Vasc Biol2000201724172810894809
   PubMed Web of Science ®Google Scholar
• ShalitoIKopylevaOSerebruanyVNovel antiplatelet agents in development: prasugrel, ticagrelor, and cangrelor and beyondAm J Ther20091645145819262362
   PubMed Web of Science ®Google Scholar
• NandaNBaoMLinHPlatelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contact-induced activationJ Biol Chem20052802468024689
   PubMed Web of Science ®Google Scholar
• SerebruanyVLStebbingJAtarDDyspnoea after antiplatelet agents: the AZD6140 controversyInt J Clin Pract200761529533
   PubMed Web of Science ®Google Scholar